Skip to main content

Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells



Malignant human embryonal carcinoma cells (ECCs) rely on similar transcriptional networks as non-malignant embryonic stem cells (ESCs) to control selfrenewal, maintain pluripotency, and inhibit differentiation. Because re-activation of silenced HERV-K(HML-2) loci is a hallmark of ECCs, we asked if this HERV group was also reactivated in ESCs and induced pluripotent stem cells (iPSCs).


Using RT-PCR and Western Blot, we demonstrate HERV-K(HML-2) RNA and protein expression in undifferentiated human ESCs and iPSCs. Induction of differentiation by embryoid body formation resulted in rapid silencing of HERV-K(HML-2) provirus expression. Sequencing analysis of a conserved region of the gag gene showed that proviral expression in ESCs and iPSCs represents at least 11 of the 66 nearly full length HERV-K(HML-2) loci, with slightly varying patterns in individual cell lines. These proviruses are human specific integrations and harbor promoter competent long terminal repeats (LTR5hs subgroup). We observed high mRNA levels of the NP9 and Gag encoding proviruses K101(22q11.21) in all and K10(5q33.3) in most of the ECC, ESC, and iPSC lines tested, while K37(11q23.3) mRNA was detected only in ESCs and iPSCs. In addition, we detected expression of proviral mRNA encoding the RNA export adaptor Rec in all cell lines studied. Proviral mRNA originating from the K108(7p22.1) locus, which inter alia codes for functional Rec and Env proteins, was only reactivated in malignant ECC lines, not in benign ESCs or iPSCs.


HERV-K(HML-2) RNA and protein expression is a marker for pluripotent human stem cells. Initiation of differentiation results in rapid down-regulation. Further studies are needed to explore a putative functional role of HERV-K(HML-2) RNA and proteins in pluripotent stem cells.


Although no infectious HERV particles have been detected to date, several proviruses of the evolutionary young hominoid group HERV-K(HML-2) harbor open reading frames for viral proteins, as well as promoter competent long terminal repeats (LTRs) [1, 2]. Two subgroups exist (Figure 1A): Type 2 proviruses encode the accessory protein Rec, which mediates nuclear-cytoplasmic translocation of incompletely spliced RNA, thereby allowing translation of viral proteins [3]. Type 1 proviruses harbor a 292-bp deletion within the pol-env boundary, resulting in loss of a functional open reading frame for Rec, but gaining a functional open reading frame for the accessory protein Np9 [4]. In vitro assays have shown that Rec and Np9 interact with cellular proteins like the promyelocytic leukemia zinc finger protein (PLZF), ligand of numb protein X (LNX), testicular zinc-finger protein, androgen receptor, and small glutamine-rich tetratricopeptide repeat protein and might thus support cell transformation [59]. Although HERV-K(HML-2) proviruses may be transcribed in somatic cells [10, 11], up-regulated transcription and protein expression, formation of retrovirus particles, and induction of an anti-HERV-K(HML-2) immune response are predominantly associated with germ cell tumors, embryonal carcinoma cell (ECC) lines, melanomas and other cancers [1217].

Figure 1

HERV-K(HML-2) expressed at RNA and protein level in ES/iPS cells. A) Prototypic HERV-K(HML-2) open reading frames B) Type 1 and 2 mRNA species, ∆ denotes the 292 bp deletion in type 1 proviruses. 1) full length type 2, 1) full length type 1, 2) env mRNA type 2, 2) env mRNA type 1, 3) 1.8 kb mRNA type 2 encoding rec[18], 3) 1.5 kb mRNA type 1 encoding Np9[4], 4) 1.5 kb mRNA derived from type 1 or type 2 [18]. PCR primers are indicated by arrows and arrowheads. Primers PrevENV, PrevREC, PrevNP9 overlap the immediate upstream splice site. C) RT-PCR of HERV-K(HML-2) expression in ES cells (H1, H9, BG01), fibroblasts (MRC5, MSC, hFib2) and corresponding iPS cells using the primer pair K20 and K6. OCT4, NANOG served as pluripotency, LMNA as differentiation markers, ACTB as internal control [19, 20]. D) Western blot for HERV-K(HML-2) Gag, OCT4 and ACTB in ES, iPS, fibroblast and EC cells.

The phenotype and transcriptional profile of ECCs resemble that of non-malignant pluripotent embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) in that they express key pluripotency factors such as OCT4, NANOG and SOX2 and other markers characteristic of pluripotent stem cells [reviewed in [21]]. In addition, ECCs rely on similar pathways to regulate self-renewal and inhibition of differentiation [21], such as autocrine FGF signalling and activation of downstream signalling cascades, especially the ERK/MEK pathway [22, 23]. These similarities prompted us to test whether HERV-K(HML-2) RNA and protein expression, which is a marker of ECCs, might also be reactivated in non-malignant pluripotent stem cells.

HERV-K(HML-2)RNA and proteins are expressed in ESCs and iPSCs

We analyzed the expression of HERV-K(HML-2) in three ESC lines (H1, H9, BG01), three fibroblast lines (MRC5, MSC, hFib2) and iPSC lines derived from these fibroblasts. All materials and methods are described in detail in Additional file 1 “Materials and Methods”. To augment the probability to detect HERV-K(HML-2) transcripts derived from proviral promoters, we analyzed completely spliced viral RNA by RT-PCR. Full length and spliced transcripts and the location of all primer pairs used are depicted in Figure 1B. We verified expression of the endogenous pluripotency genes OCT4 and NANOG and absence of the differentiation marker gene LMNA in pluripotent stem cells, ACTB specific amplicons served as internal controls [19, 20]. We did not detect any HERV-K(HML-2) specific amplicons in any of the fibroblast cell lines, which readily expressed the differentiation marker LMNA. In contrast, all ESC and iPSC lines tested showed expression of all three types of completely spliced HERV-K(HML-2) transcripts, in addition to the pluripotency markers OCT4 and NANOG (Figure 1C). The intensities of the PCR amplicons varied between individual ESC/iPSC lines, suggesting differential activation of proviruses between lines.

The presence of spliced HERV-K(HML-2) type 2 transcripts in all pluripotent stem cell lines tested prompted us to investigate whether they encode functional Rec protein and thus enable translation of HERV-K(HML-2) Gag and Env proteins. Using a HERV-K(HML-2) Gag specific monoclonal antibody in Western blot analysis, we indeed detected low to moderate levels of this protein in the H9 ESCs and the hFib2-iPS5 iPSC line, but not in the parental fibroblasts hFib2. By contrast, the ECC line GH showed high levels of Gag protein expression (Figure 1D). To ensure the phenotypic similarity between the malignant ECC line and the non-malignant ESC/iPSC lines, we verified by RT-PCR that GH cells expressed the pluripotency markers OCT4, NANOG, SOX2, STELLA as well as the autocrine signaling factor FGF4 (data not shown). The differences in HERV-K(HML-2) Gag protein levels observed in H9 and hFib2-iPS5 correlated with the differences in signal intensities of their rec specific amplicons in RT-PCRs (Figure 1C, compare intensities of amplicons 3), which is consistent with the idea that the levels of functional Rec protein determine the efficiency of Gag protein translation.

Differentiation induces silencing of HERV-K(HML-2)proviruses

To determine whether HERV-K(HML-2) expression in pluripotent stem cells changes during differentiation, we induced embryoid body formation of hFib2-iPS5 cells. We applied semi-qRT-PCR analysis using the primer pair K7/K21 (see Figure 1B). Interestingly, the levels of HERV-K(HML-2) RNA started to decrease from day 6 onwards in hFib2-iPS5 cells, concomitant with a decrease of NANOG and an increase of LMNA expression (Figure 2A). To estimate the degree of the changes we quantified the signal intensities of the RT-PCR bands visualized by ethidium bromide gel analysis (Figure 2A) relative to ACTB (see Additional file 1 “Materials and Methods”). HERV-K(HML-2) expression levels dropped from 100% on day 0 to roughly 50% on day 6, and to 20% on day 10. Similarly, NANOG expression levels decreased from 100% on day 0 to roughly 75% on day 6, and 55% on day 10.

Figure 2

HERV-K(HML-2) expression is immediately down-regulated during embryoid body differentiation. A) Semi-quantitative RT-PCR of HERV-K(HML-2) expression in hFib2- iPS5 cells using the primer pair K21 and K7. The faint band at ≈570 bp presumably represents the rec mRNA of provirus ERVK-17 (see Table 1) which contains a small deletion in the amplified region. LMNA was amplified using an alternative primer (see Additional file 1 “Materials and Methods”) B) Quantitative expression analysis of HERV-K(HML-2) env, rec and Np9 transcripts in H9 cells. OCT4, LMNA, and ACTB serve as control [19, 20]. RNA levels are depicted relative to undifferentiated cells on day 0 (n=2, error bars +/-s.e.m).

To verify this with a second method and cell line, we performed real-time RT-PCR analysis using differentiating H9 ESCs [19, 20]. This analysis showed an even more dramatic reduction of HERV-K(HML-2) RNA expression during differentiation with significantly reduced transcription already detectable on day 2 of embryoid body differentiation (Figure 2B). Remarkably, the kinetics of HERV-K(HML-2) downregulation is even faster than repression of OCT4 and NANOG.

These slightly divergent results may simply reflect the greater accuracy of real time PCR compared to semi-quantitive PCR or may be rooted in the well-known subtle differences in the expression profiles of pluripotent stem cells especially those of ESC compared to iPSC lines [24].

The recent findings that high RNA levels of the endogenous retrovirus group HERV-H [25] and expression of non-LTR retrotransposons [26] are also associated with human pluripotent stem cells indicate that a pluripotent phenotype might be accompanied by a general relieve of retroelement silencing. We therefore asked whether re-activation of HERV-K(HML-2) proviruses is specific for certain proviral elements or occurs in a stochastic manner.

HERV-K(HML-2)proviruses are activated in ESC/iPSC/ECC lines in varying patterns

We analyzed activation of HERV-K(HML-2) proviruses in malignant and non-malignant pluripotent stem cells using an established protocol [27] to amplify, clone, and sequence a highly conserved part of the gag gene (see Additional file 1 “Materials and Methods”). A proviral sequence was scored as the genomic origin of the respective clone when the two sequences exerted more than 98% identity (Additional file 2 “Alignments”, .msf files of these alignments are available as Additional files 3 “K101(22q11.21)”, 4 “K10(5q33.3)”, 5 “K106(3q13.2)”, 6 “K115(8p23.1)”, 7 “K37(11q23.3)”, 8 “K102(1q22)”, 9 “K108(7p22.1)”, 10 “HKc10-B(10q24.2)”, 11 “K41(12q14.1)”, 12 “K109(6q14.1)” and 13 “KI(3q21.2)”). Out of the 66 full-length or nearly full-length HERV-K(HML-2) proviruses present in the human genome [1], a subset of 11 were found to be expressed in patterns, which varied from cell line to cell line (Table 1). More activated loci may be detected using optimized primers [28], deep sequencing techniques [29] as well as more cell lines. Notably, all transcribed loci belong to the LTR5Hs subgroup of HERV-K(HML-2) proviruses. Interestingly, phylogenetic classifications have shown that all human-specific retroviral integrations fall into this proviral subgroup [1]. Indeed, ten of the expressed proviruses were human-specific, while K37(11q23.3) may also be present in the genomes of great apes. Five of the re-activated proviruses belonged to type 1 and six to type 2 genotypes, respectively, but their number and expression levels varied between individual ESC/iPSC and ECC cell lines. Such variations in HERV-K(HML-2) proviral transcription profiles are commonly observed in somatic malignant and non-malignant tissues and cell lines [10, 28] indicating a somewhat stochastic re-activation mechanism which may reflect varying chromatin dynamics [30]. By contrast, we observed constant and efficient transcription of the type 1 provirus K101(22q11.21) in all pluripotent stem cell lines tested, suggesting a more directed re-activation. K101(22q11.21), K37(11q23.3) and K10(5q33.3) encode gag and protease genes and may account for the protein expression detected, e.g. in the H9 and hFib2-iPS5 lines (Figure 1D). Transcription of one or the other type 2 locus was detected in the ESC/iPSC lines, but only at low level. This is in contrast to the observed constant up-regulation of K108(7p22.1) expression exclusively in the malignant ECC lines. Notably, a recent survey of HERV-K(HML-2) proviruses transcribed in melanomas in comparison to melanocytes also demonstrated K108(7p22.1) derived mRNA only in melanomas but not in the non-malignant precursor cells [28].

Table 1 Relative cloning frequencies of HERV-K(HML-2) loci transcribed in ESC, iPSC and ECC lines


The endogenous betaretrovirus group HERV-K(HML-2) is unique in its potential to code for viral and accessory proteins. We observed, in slightly varying patterns, re-activation at the RNA and protein levels of certain human specific, protein encoding HERV-K(HML-2) proviruses with promoter competent LTR sequences in pluripotent ESCs, iPSCs, and ECCs. The surprisingly constant activation of K101(22q11.21) across all cell lines tested may indicate a particular function in or association with pluripotency. We detected K108(7p22.1) only in the malignant ECC lines. This corresponds to up-regulated K108(7p22.1) transcription described in other germ cell tumours, in brain tumours but not in normal brain [10] as well as in malignant melanoma [28] but not in melanocytes. HERV-K(HML-2) proviruses were rapidly silenced upon embryoid body differentiation. Re-activation of this HERV group thus represents another marker for the undifferentiated state of pluripotent stem cells.

Active type 2 proviruses produce Rec protein, which supports cell transformation in vitro and germ line carcinoma in situ in transgenic mice [7, 31]. Type 1 proviruses produce Np9 protein [4]. Both Rec and Np9 interact with transcriptional regulators. For example, Rec and Np9 bind the MYC repressor PLZF resulting in overexpression of MYC [6] and Np9 can bind to LNX [8] which might influence the activity of the NOTCH pathway. MYC and NOTCH are often involved in carcinogenesis but are also important players in the signalling networks controlling self-renewal, pluripotency and differentiation [32]. Since there are substantial differences between the cell cycle regulation of murine and human pluripotent stem cells [21], it is intriguing to speculate that Rec and Np9, which are not encoded by rodent ERVs, might play positive roles in human ESC/iPSCs. The observation that Rec and Np9 encoding HERV-K(HML-2) proviruses were preferentially activated in pluripotent stem cells and that their expression was simultaneously silenced upon differentiation independent of their chromosomal localization is in favour of such an idea.


  1. 1.

    Subramanian RP, Wildschutte JH, Russo C, Coffin JM: Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology. 2011, 8: 90-10.1186/1742-4690-8-90.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  2. 2.

    Fuchs NV, Kraft M, Tondera C, Hanschmann KM, Lower J, Lower R: Expression of the human endogenous retrovirus group HML-2/HERV-K does not depend on canonical promoter elements but is regulated by the transcription factors Sp1 and Sp3. J Virol. 2011, 85: 3436-3448. 10.1128/JVI.02539-10.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  3. 3.

    Magin C, Lower R, Lower J: cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K. J Virol. 1999, 73: 9496-9507.

    PubMed Central  CAS  PubMed  Google Scholar 

  4. 4.

    Armbruester V, Sauter M, Krautkraemer E, Meese E, Kleiman A, Best B, et al: A novel gene from the human endogenous retrovirus K expressed in transformed cells. Clin Cancer Res. 2002, 8: 1800-1807.

    CAS  PubMed  Google Scholar 

  5. 5.

    Kaufmann S, Sauter M, Schmitt M, Baumert B, Best B, Boese A, et al: Human endogenous retrovirus protein Rec interacts with the testicular zinc-finger protein and androgen receptor. J Gen Virol. 2010, 91: 1494-1502. 10.1099/vir.0.014241-0.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N: Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J Virol. 2007, 81: 5607-5616. 10.1128/JVI.02771-06.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  7. 7.

    Boese A, Sauter M, Galli U, Best B, Herbst H, Mayer J, et al: Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein. Oncogene. 2000, 19: 4328-4336. 10.1038/sj.onc.1203794.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Armbruester V, Sauter M, Roemer K, Best B, Hahn S, Nty A, et al: Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X. J Virol. 2004, 78: 10310-10319. 10.1128/JVI.78.19.10310-10319.2004.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  9. 9.

    Hanke K, Chudak C, Kurth R, Bannert N: The Rec protein of HERV-K(HML-2) upregulates androgen receptor activity by binding to the human small glutamine-rich tetratricopeptide repeat protein (hSGT). Int J Cancer. 2013, 132: 556-567. 10.1002/ijc.27693.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Flockerzi A, Ruggieri A, Frank O, Sauter M, Maldener E, Kopper B, et al: Expression patterns of transcribed human endogenous retrovirus HERV-K(HML-2) loci in human tissues and the need for a HERV Transcriptome Project. BMC Genomics. 2008, 9: 354-10.1186/1471-2164-9-354.

    PubMed Central  Article  PubMed  Google Scholar 

  11. 11.

    Seifarth W, Frank O, Zeilfelder U, Spiess B, Greenwood AD, Hehlmann R, et al: Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray. J Virol. 2005, 79: 341-352. 10.1128/JVI.79.1.341-352.2005.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  12. 12.

    Kleiman A, Senyuta N, Tryakin A, Sauter M, Karseladze A, Tjulandin S, et al: HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors. Int J Cancer. 2004, 110: 459-461. 10.1002/ijc.11649.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Wang-Johanning F, Liu J, Rycaj K, Huang M, Tsai K, Rosen DG, et al: Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer. 2007, 120: 81-90. 10.1002/ijc.22256.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Humer J, Waltenberger A, Grassauer A, Kurz M, Valencak J, Rapberger R, et al: Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses. Cancer Res. 2006, 66: 1658-1663. 10.1158/0008-5472.CAN-05-2452.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Hahn S, Ugurel S, Hanschmann KM, Strobel H, Tondera C, Schadendorf D, et al: Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses. 2008, 24: 717-723. 10.1089/aid.2007.0286.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, et al: Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst. 2012, 104: 189-210. 10.1093/jnci/djr540.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  17. 17.

    Lower R: The pathogenic potential of endogenous retroviruses: facts and fantasies. Trends Microbiol. 1999, 7: 350-356. 10.1016/S0966-842X(99)01565-6.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Lower R, Boller K, Hasenmaier B, Korbmacher C, Muller-Lantzsch N, Lower J, et al: Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci U S A. 1993, 90: 4480-4484. 10.1073/pnas.90.10.4480.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  19. 19.

    Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008, 451: 141-146. 10.1038/nature06534.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al: Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010, 42: 1113-1117. 10.1038/ng.710.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  21. 21.

    Jaenisch R, Young R: Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell. 2008, 132: 567-582. 10.1016/j.cell.2008.01.015.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  22. 22.

    Armstrong L, Hughes O, Yung S, Hyslop L, Stewart R, Wappler I, et al: The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum Mol Genet. 2006, 15: 1894-1913. 10.1093/hmg/ddl112.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Chen G, Gulbranson DR, Yu P, Hou Z, Thomson JA: Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells. Stem Cells. 2012, 30: 623-630. 10.1002/stem.1021.

    PubMed Central  Article  PubMed  Google Scholar 

  24. 24.

    Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, Smith ZD, et al: Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell. 2011, 144: 439-452. 10.1016/j.cell.2010.12.032.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  25. 25.

    Santoni FA, Guerra J, Luban J: HERV-H RNA is abundant in human embryonic stem cells and a precise marker for pluripotency. Retrovirology. 2012, 9: 111-10.1186/1742-4690-9-111.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  26. 26.

    Wissing S, Munoz-Lopez M, Macia A, Yang Z, Montano M, Collins W, et al: Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility. Hum Mol Genet. 2012, 21: 208-218. 10.1093/hmg/ddr455.

    PubMed Central  Article  PubMed  Google Scholar 

  27. 27.

    Ruprecht K, Ferreira H, Flockerzi A, Wahl S, Sauter M, Mayer J, et al: Human endogenous retrovirus family HERV-K(HML-2) RNA transcripts are selectively packaged into retroviral particles produced by the human germ cell tumor line Tera-1 and originate mainly from a provirus on chromosome 22q11.21. J Virol. 2008, 82: 10008-10016. 10.1128/JVI.01016-08.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  28. 28.

    Schmitt K, Reichrath J, Roesch A, Meese E, Mayer J: Transcriptional Profiling of Human Endogenous Retrovirus Group HERV-K(HML-2) Loci in Melanoma. Genome Biol Evol. 2013, 5: 307-328. 10.1093/gbe/evt010.

    PubMed Central  Article  PubMed  Google Scholar 

  29. 29.

    Paces J, Huang YT, Paces V, Ridl J, Chang CM: New insight into transcription of human endogenous retroviral elements. N Biotechnol. 2013, 30: 314-318. 10.1016/j.nbt.2012.11.009.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Vinuelas J, Kaneko G, Coulon A, Vallin E, Morin V, Mejia-Pous C, et al: Quantifying the contribution of chromatin dynamics to stochastic gene expression reveals long, locus-dependent periods between transcriptional bursts. BMC Biol. 2013, 11: 15-10.1186/1741-7007-11-15.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  31. 31.

    Galli UM, Sauter M, Lecher B, Maurer S, Herbst H, Roemer K, et al: Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors. Oncogene. 2005, 24: 3223-3228. 10.1038/sj.onc.1208543.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Singh AM, Dalton S: The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell. 2009, 5: 141-149. 10.1016/j.stem.2009.07.003.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

Download references


K. Boller (Paul-Ehrlich-Institute, Langen, Germany) has kindly provided the HERMA6/7 antibodies. We thank Christiane Tondera and Heike Strobel (Paul-Ehrlich-Institute, Langen, Germany) for excellent technical assistance. Also, we would like to express our gratitude to G. Schumann and S. Klawitter (Paul-Ehrlich-Institute, Langen, Germany) for stimulating discussions and K. Cichutek (President of the Paul-Ehrlich-Institute, Langen, Germany) for his constant support.

Author information



Corresponding authors

Correspondence to Nina V Fuchs or Johannes Löwer.

Additional information

Competing interests

The authors declare that no competing interests exist.

Authors’ contributions

NVF, SL and RL conceived the study and performed the analyses. NVF did HERV-K(HML-2) cloning, performed the sequence analysis and did the immunoblot assay. SL performed cell culture, embryoid body differentiation and RT-PCR analysis. GQD supplied the cells. ZI and GQD financially supported the study. JL helped interpret the results. NVF, SL, JL and RL wrote the manuscript. All authors have read and approved the submission of the manuscript.

Nina V Fuchs, Sabine Loewer contributed equally to this work.

Electronic supplementary material

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Fuchs, N.V., Loewer, S., Daley, G.Q. et al. Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells. Retrovirology 10, 115 (2013).

Download citation


  • Human embryonic stem cells
  • Induced pluripotent stem cells
  • Activation of human endogenous retrovirus K proviruses
  • Embryoid body differentiation
  • Pluripotency marker